Androgenetic alopecia
Co-authored with Yuliia Kachuk
Ovcharenko Yu.S., Kachuk Yu.V. Androgenetic alopecia // Человек и лекарство. – Almaty, 2015 – pp. 27-32 (original in Russian)
Androgenetic alopecia (AGA) is a complex polygenic condition and the most common form of hair loss, affecting up to 80% of men and 50% of women during their lifetime [1]. Given how widespread the condition is, some experts regard AGA as an organ-specific accelerated ageing process, with hair follicle fibroblasts showing increased sensitivity to oxidative stress [2].
Genetics
A family history of AGA, which points to a strong genetic predisposition, considerably increases the risk of developing the condition. The mechanisms by which male and female pattern hair loss are inherited are not fully understood. Various gene loci have been proposed as being involved in the hereditary transmission of AGA: the androgen receptor gene on the X chromosome, the insulin-like growth factor-1 gene locus on chromosome 12, the cytochrome 450c17alpha gene on chromosome 10 and the gene of the enzyme 5α-reductase (SRD5A1 on chromosome 5 and SRD5A2 on chromosome 2). Recently, a gene locus associated with male pattern baldness was identified on chromosome 20p11.22. This gene locus is thought to play a possible role in an androgen-independent pathway of the disease [3].
Pathobiology of androgenetic alopecia
Genetically predisposed hair follicles (HF) in the affected areas are thought to undergo a stepwise, androgen-dependent replacement of pigmented terminal hairs by barely visible, depigmented vellus hairs. The process is marked by a progressive shortening of successive growth phases in the hair cycle, which reduces the number of hairs in anagen at any given time, and by progressive follicular miniaturisation, with terminal follicles turning into vellus-like ones [4]. As a result, shedding of hairs in the resting or telogen phase increases (telogen effluvium), while the affected HF produces shorter and finer hairs. In addition, the interval between the shedding of a hair and the return of anagen lengthens, so the number of hairs on the scalp falls, much as in involutional alopecia [5].
Alongside the clearly defined genetic component, considerable progress has been made in understanding the key elements of the metabolism of the androgens involved. Androgen-dependent processes occur mainly through the binding of dihydrotestosterone (DHT) to the androgen receptor (AR). DHT-dependent cell functions are determined by the presence of weak androgens, their conversion into more potent androgens by 5-alpha reductase, low activity of the enzymes that inactivate androgens, and the presence of large amounts of functionally active AR. High DHT levels and increased AR expression have been recorded in the predisposed scalp. A key role is assigned to the conversion of testosterone into DHT in the dermal papilla, while androgen-regulated factors produced by dermal papilla cells are thought to influence the growth of the other components of the HF [4].
Although AGA is not an inflammatory type of hair loss, the early histological changes consist of non-specific focal perivascular basophilic degeneration in the lower third of the connective tissue sheath, followed by a mild to moderate perifollicular lymphocytic infiltrate at the level of the sebaceous duct. As the condition progresses further, multinucleated giant cells may form [6].
Clinical and research progress has helped to clarify some of the pathogenic steps leading to androgenetic hair loss. Besides androgens and genetic imbalance, additional pathogenic factors are thought to be involved: the microbial flora, endogenous and exogenous stresses, microinflammation and possibly others. Although further potential factors will undoubtedly be identified, any review of the biological conditions that favour androgenetic alopecia must also take into account the individual diversity of triggers, as well as the sequence of events or the combination of factors.
Microinflammation of the hair follicle and fibrosis in AGA
The involvement of microscopic follicular inflammation in the pathogenesis of androgenetic alopecia has been shown in several independent studies [7, 8, 9]. Early studies described an inflammatory infiltrate of activated T cells and macrophages in the upper third of the hair follicle, accompanied by thickening of the follicular dermal sheath made up of collagen bundles (perifollicular fibrosis) in areas of actively progressing hair loss [7]. Analysis of horizontal sections of scalp biopsies mostly showed moderate perifollicular fibrosis consisting of loose concentric layers of collagen, which should be distinguished from scarring alopecia [9]. The term "microinflammation" was proposed because the process follows a slow, subtle and painless course, unlike the inflammatory and destructive process of classic inflammation in scarring alopecia [8].
Inflammation is seen as a multistep process that begins with a primary event. The presence of a perifollicular infiltrate in the upper part of the follicle near the infundibulum suggests that the main event triggering the inflammation may take place close to it. Given this location and the colonisation of the follicular infundibulum by Propionibacterium spp., Staphylococcus spp., Malassezia spp. or other non-resident flora, microbial toxins or antigens may be involved in generating the inflammatory response. In addition, the production of porphyrins by Propionibacterium spp in the pilosebaceous duct is considered a possible cofactor of this initial pro-inflammatory stress [8]. However, keratinocytes themselves can respond to chemical stress from irritants, pollutants and UV radiation by producing reactive oxygen species and nitric oxide and by releasing intracellularly stored IL-1α. This pro-inflammatory cytokine has itself been shown to inhibit the growth of isolated hair follicles in culture [10]. Moreover, neighbouring fibroblasts are also fully equipped to respond to such a pro-inflammatory signal. As a result, if the triggers persist, a lasting inflammation develops with remodelling of the connective tissue, in which collagenases such as matrix metalloproteinases (whose transcription is also driven by pro-inflammatory cytokines) play an active role. Collagenases are thought to take part in the tissue changes of perifollicular fibrosis [8].
Clinical features
In the typical presentation of AGA in men, the frontotemporal area and the vertex are affected. Men may, however, develop diffuse thinning over the vertex with the frontal hairline preserved, resembling the female pattern of hair loss. In women with AGA, three clinical patterns are distinguished: diffuse thinning over the parietal area with the frontal hairline preserved; the so-called "Christmas tree" pattern, with diffuse thinning of the central scalp and relative preservation of the frontal hairline; and thinning with bitemporal recession of the frontal hairline, resembling the male pattern. In women, AGA may begin early, as soon as adolescence, or late, coinciding with the menopause [4].
Although patients with pattern hair loss periodically go through episodes of shedding and worsening, thinning in androgenetic alopecia usually progresses gradually and speeds up as the patient gets older. The final extent of hair loss, the age of onset and the pattern all vary from person to person. In older patients, involutional alopecia and pattern hair loss usually develop at the same time, and the two distinct conditions can be difficult to tell apart [5].
Dermoscopy
The dermoscopic signs of AGA are hair shaft diameter diversity, the empty follicle phenomenon, peripilar signs, pigmentation and inflammation of the scalp [1].
Hair diameter diversity is a characteristic diagnostic sign of AGA, affecting > 20% of hairs in the androgen-dependent areas. Under the influence of androgens, hair follicles undergo progressive miniaturisation, and the hair they produce gradually becomes finer and less pigmented. In severe forms of AGA, miniaturisation affects the follicles diffusely and the hair thins evenly. The empty follicle phenomenon is the presence of yellow dots on the scalp that correspond to empty follicles. The yellow colour comes from the follicular openings, dilated to a greater or lesser degree, being filled with sebum produced by the sebaceous glands. Pigmentation is a non-specific sign of AGA that is nevertheless common, especially in severe forms. It is a reticular, honeycomb pigmentation of the interfollicular epidermis, clearly visible at 40–50x magnification. This dark pigmentation is caused by increased sun exposure of a scalp that is not sufficiently covered by hair. Peripilar signs, also called peripilar rings, look like a dark halo about 1 mm in size around the follicular opening from which the hair emerges. In 2004 Deloche demonstrated trichoscopically the presence of "peripilar signs" in AGA and their correlation with superficial perifollicular inflammation in this condition. Inflammation: the scalp of patients with AGA is often (to a greater or lesser degree) erythematous, and the redness may be diffuse or patchy. In most cases the erythema is caused by inflammation due to seborrhoeic dermatitis. At high magnification (40x) the erythema corresponds to dilated capillaries in the superficial dermis, which in seborrhoeic dermatitis usually form irregular loops. Redness of the scalp was first described by Thestrup-Pedersen and Hjorth [11], and later by Moschella [12], who reported the problem of "diffuse redness of the scalp, which may also be accompanied by itching and burning". Patients often report that the condition worsens in the sun, or that they have had sunburn on the scalp. The most widely held views on its pathogenesis are perifollicular inflammation and increased expression of the neuropeptide substance P in the immediate vicinity of the affected HF [13]. In a published case series of 403 patients complaining of hair loss who were examined for trichodynia, its presence correlated strongly with scalp telangiectasia found on dermoscopy [14].
Therapeutic strategies: today and tomorrow
To date, the effects of oxidative stress, the inflammatory component and developing fibrosis have not been addressed in treatment protocols for androgenetic alopecia. A careful analysis of the molecular controls of the immune-driven physiological degeneration of the hair follicle through apoptosis-mediated organ death will help us understand how to halt the progression of some forms of permanent hair loss, which current treatments can only partly halt. This also applies to further research into androgenetic alopecia with inflammatory processes and fibrosis.
The current treatments for AGA with proven efficacy are oral finasteride, a type 2 5-alpha reductase inhibitor, and topical minoxidil, an adenosine triphosphate (ATP)-sensitive potassium channel opener that is reported to stimulate VEGF production in cultured dermal papilla cells. Second-line treatments for AGA in women are androgen antagonists, including finasteride, cyproterone acetate, flutamide and spironolactone, whose use is limited by a number of contraindications and an insufficient response to treatment. Hair transplantation is an exceptional treatment option for patients with AGA [15]. Traditionally, combined therapy for patients with hair disorders includes metabolic complexes containing amino acids, pantothenic acid, biotin and their combinations, as well as a combination of L-cystine, medicinal yeast and pantothenic acid (CYP complex) [16]. Implantation of dermal papilla cells or follicular dermal sheath cells is reported to become available soon for treating men and women with AGA [17]. Promising directions in the aetiopathogenetic treatment of AGA under discussion include antimicrobial shampoos in therapeutic and preventive care, as well as methods with a marked antioxidant and anti-inflammatory action [5].
Diagnosis and treatment at the Institute
Get a consultation
Modifiers of androgen metabolism: finasteride
The rationale for using finasteride to treat AGA in men rests on the absence of androgenetic alopecia in men with congenital type 2 5-alpha reductase deficiency, and on the increased 5-alpha reductase activity and DHT levels in the balding scalp [1]. The oral form of the drug lowers DHT levels in serum and in the scalp. Finasteride 1 mg/day was approved for the treatment of AGA in men in 1998. Randomised clinical trials have confirmed that finasteride 1 mg/day can prevent or slow hair loss in most men, with about two thirds of trial participants showing improvement. A slight increase in sexual dysfunction was noted during the clinical trials, but these side effects resolved once finasteride was stopped.
Oral finasteride at 2.5 or 5 mg a day may be prescribed only to postmenopausal women or to women who are taking oral contraceptives at the same time. The drug is contraindicated in women planning a pregnancy (or already pregnant), as it may block the development of the genitals in a male foetus. A recent study showed that oral finasteride, 5 mg/day, may be an effective and safe treatment for women with AGA and normal androgen levels [1].
With the safety of AGA treatment in mind, Swiss scientists have developed a new proprietary product, P-3074, a 0.25% finasteride lotion for topical use. In clinical testing it lowers the DHT concentration in the scalp skin by 40 % more than oral finasteride [18].
Antiandrogens
Oral antiandrogens such as spironolactone and cyproterone acetate are used in women with signs of hyperandrogenism, as they compete with androgens for the androgen receptors. Cyproterone acetate prevents 5α-DHT from binding to the androgen receptor and, through its progestogenic action, also inhibits the secretion of FSH and LH. For women with hyperandrogenism the recommended dose is 100 mg/day, taken during the first 10 days of the menstrual cycle; for postmenopausal women a dose of 50 mg/day is recommended. Because of the risk of feminising a male foetus, these drugs must be taken together with an oestrogen (ethinylestradiol or oral contraceptives). Side effects include loss of libido, mood swings, fatigue, mastodynia, hypertension and weight gain. The drug is contraindicated in patients with liver disease. Spironolactone is an aldosterone antagonist and an inhibitor of androgen synthesis. At a dose of 200 mg a day it is effective in stimulating hair growth in women [1].
Hair growth stimulants: minoxidil
Minoxidil was developed to treat arterial hypertension. This action of the drug is well understood, unlike its mechanism of action on hair growth, which is still being studied. Minoxidil promotes hair growth by prolonging the anagen phase, enlarging the follicles and stimulating the growth of resting HF. As a potassium channel opener and vasodilator, it stimulates VEGF production in cultured dermal papilla cells. There is evidence that this effect is mediated by sulfonylurea and adenosine receptors, well-known targets of ATP-sensitive potassium channel openers. Minoxidil is applied in a dose of 1 ml to the dry scalp twice a day (for the 2% and 5% formulations), spread evenly over the affected areas and left on for at least 4 hours. If topical minoxidil is stopped, hair loss resumes after 8-12 weeks, and all the regrown hair is gradually lost. And although minoxidil is today probably the most accessible and effective agent of proven action with a marked hair growth stimulating effect, only 40% of patients respond to it [15].
Metabolic complexes
It is beyond dispute that the HF is one of the most metabolically active structures of the human body and therefore needs certain components and energy sources to produce healthy hair: amino acids, vitamins, trace elements and polyunsaturated fatty acids. Products based on L-cystine combined with B vitamins (CYP complex) have an evidence base for treating hair loss, which rests on the biochemistry of cystine metabolism, clinical observations of impaired cystine metabolism and cystine deficiency, and the results of studies of these products [16].
Surgical hair restoration
Surgery as a treatment for AGA usually means redistributing terminal hairs to cover a part of the thinning scalp, while the number of HF stays the same. Other, more invasive methods (for example, scalp reduction and flaps) are less common in current clinical practice. In men, grafts of 1-2 follicular units from the occipital scalp are transplanted to the thinning areas using a hypodermic needle or a scalpel. In female patients the operation is performed in the same way, but the donor area may be more limited, as women's hairstyles do not allow the temporal and lower parietal or occipital areas to be used as donor sites.
Follicular unit transplantation can give very good results, but the success of the operation depends on careful patient selection and the skill of the surgeons. Hair density in the donor area must be optimal, and correction of frontal hair loss gives better results than correction of the vertex, where the disease tends to progress even after transplantation. The patient's expectations must be realistic: they should know that the final result may only be visible after several sessions, at 5-6 months. Patients should also know that temporary hair loss may occur in the donor and recipient areas. As with any surgery, the risk of complications must be considered, such as erythema, crusting and swelling, as well as more serious infection, bleeding and scarring. Hair transplantation is also a fairly expensive procedure [1].
The limited possibilities of hair transplantation and the modest efficacy of finasteride and minoxidil in treating androgenetic alopecia show that other pathogenic pathways need to be considered. Histological studies of scalp biopsies show that miniaturisation of terminal hairs is often accompanied by perifollicular lymphocytic infiltration and eventually fibrosis [7,9]. It can therefore be assumed that the role of this microscopic follicular inflammation, which causes fibrosis beneath the shortened balding follicle, has not been properly assessed, although it very likely prevents the renewal of the terminal HF.
Anti-inflammatory agents, antioxidants and antifibrotic agents are not part of the standard treatment of androgenetic alopecia. This raises the question of whether adding them might improve patients' response to therapy.
Thus, conventional therapy combined synergistically with indirect action on the trigger factors of AGA is aetiopathogenetically justified. In our view, a promising approach in this field is the use of Predermal, a product containing 0.55% hyaluronic acid and 1.6% sodium succinate. The discovery of the many-sided biological role of succinic and hyaluronic acids has increased interest in these promising compounds. Succinic acid and its salts (succinates) are intracellular metabolites. By acting on the Krebs cycle, succinic acid reduces the formation of pyruvate and lactate, which appear under oxygen deficiency (hypoxia), and switches energy metabolism to a more economical pathway. Studies have shown that succinic acid normalises the levels of the inflammatory mediators histamine and serotonin and improves microcirculation in organs and tissues without changing systemic haemodynamics. Exogenous succinate has been found to have a moderate antihypoxic effect, improving the uptake of circulating oxygen and making cells more resistant to hypoxia. The catabolism of succinic acid involves the utilisation of other organic acids, which helps restore the acid-base balance and prevents inflammatory acidosis, for example after excessive sun exposure [19]. The normalising effect of succinate on cellular energy metabolism has been shown in experimental studies in ageing animals. The high-molecular-weight hyaluronic acid in Predermal promotes hydration and suppresses uncontrolled angiogenesis and the production of the cytokine IL-1b and prostaglandin E2; it has an immunosuppressive and detoxifying effect, and improves drainage [20,21]. The active ingredients of this unique combination complement each other: adding sodium succinate enhances the ability of hyaluronic acid to stimulate metabolic processes. This combined product is recommended for correcting scar-altered tissue [22], including striae, as well as signs of skin photoageing and chronological ageing [23]. The efficacy of these components in geroprotection has been confirmed clinically and has a solid scientific basis [24]. Thus, the synergy of the marked antioxidant action of hyaluronic acid and sodium succinate alters intracellular redox processes, thereby reducing the susceptibility of the cells' receptor apparatus to adverse environmental influences. Studies have shown that succinic acid suppresses inflammation by normalising the levels of the inflammatory mediators histamine and serotonin, and stimulates extracellular matrix proteins. The metabolic action of succinic acid is linked to the stimulation of protein synthesis and faster regeneration of damaged cells [25], which is of prime importance in restoring the HF. Also important is the capillary-protective ability of succinic acid, which improves blood microcirculation [20].
Given the pharmacological properties, metabolic activity and substantial evidence base for Predermal, we included it in the combined therapy of patients with AGA.
Materials and methods
The aim of our work was to study the efficacy and tolerability of Predermal in the combined treatment of AGA in women. At the Trichology Institute clinic we followed 20 women aged 20 to 55 diagnosed with AGA of Ludwig stages I-III. Exclusion criteria were acute organic diseases at the time of observation, sensitivity to the components of the product, and previous use of medicines with a potential hair growth stimulating effect. Before and after treatment, all patients underwent the following examinations: a dermatological examination and history of the underlying disease; trichoscopy with a dedicated ARAMO camera (Republic of Korea) with a x60 lens; a phototrichogram using the specialised diagnostic software TrichoSciencePro©; and digital photographic documentation (Nikon D70).
The patients showed typical pattern thinning; microscopy of the hair roots showed their characteristic miniaturisation; unlike the occipital area, the androgen-dependent areas showed anisotrichosis, yellow dots and an increased number of thinned hairs (on average more than 20%); there was also an increased proportion of telogen hairs (on average up to 33%); the hair pull test was weakly positive and was found in the frontoparietal area of the scalp in 11 of the 20 patients, unlike the occipital area.
To assess the efficacy of adding Predermal to the combined therapy of AGA, all patients were randomised by age, duration and severity of the disease into two comparable groups. Observation group I comprised 10 patients who received 2% topical minoxidil, 1ml twice a day. Factors that could affect the efficacy of treatment and the possible development of relapses were taken into account: the clinical features of AGA and the patients' age. An assessment was made of the factors needed to choose the right treatment approach, and the presence of concomitant diseases and the possibility of post-treatment complications were established. Group II (10 patients) was prescribed 2% topical minoxidil, 1ml twice a day, and Predermal, consisting of 0.55% hyaluronic acid and 1.6% sodium succinate, was added to their combined therapy. Predermal was administered once every 14 days for 12 weeks. Course: 6 procedures. The medium-depth nappage technique was used. Injections were made along imaginary lines dividing the treatment area into squares of 1cm x 1cm, extending 1.5 cm beyond the perimeter of this area.
Study results
The follow-up examination was carried out 12 weeks after the start of treatment. Changes in the main morphometric hair parameters (density, diameter, growth phases, number of vellus-like hairs) in patients of groups I and II are shown in Table 1.
| Parameter | Group I (n=10) | Group II (n=10) | ||
| Before treatment | After treatment | Before treatment | After treatment | |
| Hair density, hairs per 1 cm2 | 261±3.4 | 275±2.5 | 262±2.5 | 280±2.4 |
| Mean hair diameter, µm | 57±1.3 | 60±1.4 | 56±1.2 | 61±1.1 |
| Vellus-like hairs, % | 21±0.9 | 18±0.8 | 20±0.5 | 14±0.5 |
| Telogen hairs, % | 33±0.9 | 17±0.7 | 32±0.6 | 15±0.5 |
By subjective assessment, the greatest satisfaction with the treatment was reported by patients in group II. Subjectively, after combined treatment with minoxidil plus Predermal, 8 patients noted less shedding, 10 an improved appearance and 7 faster growth; in addition, 6 noticed a general improvement of the skin (less tenderness and oiliness of the scalp). All patients in group II reported good tolerability and almost no side effects. Comparative macro photographs show acceptable cosmetic results of treatment with the product. The hair pull test was negative in 100% of group II patients. No skin irritation was recorded in any case. Our observations showed that Predermal is effective and safe in the combined correction of AGA in women. To improve and maintain the result, combined therapy is recommended for up to 6 months in a maintenance regimen of 1 injection procedure once a month.
Summary
Some experts regard AGA as an organ-specific accelerated ageing process, with hair follicle fibroblasts showing increased sensitivity to oxidative stress. In androgenetic alopecia, genetically predisposed hair follicles tend to miniaturise under androgen stimulation, so that pigmented terminal hairs are replaced by barely visible depigmented hairs. This leads to a progressive loss of visible hair density on the head, following a pattern that depends on age and sex. Considerable progress has been made in understanding the metabolism of the androgens involved. Yet clinical practice has shown that simply blocking androgens does not give significant results. Histological studies show that miniaturisation of terminal hairs is often accompanied by perifollicular inflammation and eventually fibrosis. Persistent microscopic follicular inflammation with connective tissue remodelling, which ultimately leads to permanent hair loss, is therefore considered a possible cofactor in the complex aetiology of androgenetic alopecia. We have proposed a combined approach to treating AGA in women that pairs conventional therapy with a hyaluronic acid and sodium succinate product, and it has proved effective and safe.
Key references
- Трихология / А. Злотогорский, Д. Шапиро [и др.]; под ред. А. Литуса; пер. с англ. Ю. Овчаренко. – К.: Рудь, 2013. – 160 с., ил.
- Trüeb R.M. Hormone und Haarwachstum // Hautarzt. — 2010. — 61:487–95.
- Trueb R.M. Aging of hair // J Cosmet Dermatol. – 2005. – 4: 60–72.
- Blume-Peytavi U, Blumeyer A, Tosti A et al. S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents. Br J Dermatol 2011; 164: 5-15.
- Ralph M. Trüeb. Desmond J. Tobin (Eds.) Aging Hair — Springer, 2010. — 270 p.
- Sperling LC, Lupton GP (1995) Histopathology of nonscarring alopecia. J Cutan Pathol:97–114
- Jaworsky C, Kligman AM, Murphy GF (1992) Characterisation of inflammatory infiltrates in male pattern alopecia: implication for pathogenesis. Br J Dermatol 127: 239–246
- Mahe YF, Michelet JF, Billoni N, Jarrousse F, Buan B, Commo S, Seint-Leger D, Bernard BA (2000) Androgenetic alopecia and microinflammation. Int J Dermatol 39: 576–584
- Whiting DA (1993) Diagnostic and predictive value of horizontal sections of scalp biopsy specimens in male pattern androgenetic alopecia. J Am Acad Dermatol 28:755–763
- Philpott MP, Sander DA, Bowen J, Kealey T (1996) Effects of interleukins, colony stimulating factor and tumour necrosis factor on human hair follicle growth in vitro: a possible role for interleukin-1 and tumour necrosis factor-alpha in alopecia areata Br J Dermatol 135:942–948
- Thestrup-Pedersen K, Hjorth N (1987) Rod skalp. En ikke tidligere beskrevet harbundssygdom? Ugeskr Laeger 149: 2141–2142
- Moschella SL (1994) Written personal communication. August 14, 1992. In: Bernhard JD (ed) Itch. Mechanisms and management of pruritus. McGraw-Hill, New York, p 51
- Trьeb RM (2000) Molecular mechanisms of androgenetic alopecia. Exp Gerontol 37:981–990
- Willimann B, Trьeb RM (2002) Hair pain (trichodynia): frequencyand relationship to hair loss and patient gender. Dermatology 205:374–377
- Blumeyer A, Tosti A, Messenger A et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. J Dtsch Dermatol Ges 2011; 9: S1-S57.
- Trueb R.M. et al., The Value of Dietary Supplements: Results of a Double-Blind Placebo-Controlled Study with Oral Combination of Cystine, Yeast and Pantothenic Acid. - 2005
- Li L., Mignone J., Yang M., Matic M., Penman S., Enikolopov G., Hoffman R.M. Nestin expression in hair follicle sheath progenitor cells // Proc Natl Acad Sci. – 2003.–USA 100: 9958–9961.
- Hajheydari Z, Akbari J, Saeedi M, Shokoohi L. Comparing the therapeutic effects of finasteride gel and tablet in treatment of the androgenetic alopecia. Indian J Dermatol Venereol Leprol 2009;75:47-51
- Наумчик Г., Юцковская Я. РЕДЕРМАЛИЗАЦИЯ ПЕРИОРБИТЕЛЬНОЙ ЗОНЫ Эстетическая медицина, 2014.-N 2.-С.253-255.
- К вопросу об экзогенной регуляции физиологической регенерации кожи человека. В.А. Березовский, О.В. Богомолец, Н.Н.Деркач, И.Г. Литовка, С.П. Весельский, Л.Л. Лукаш, Т.А. Рубан, Р.В. Янко - Украинский журнал дерматологии, венерологии, косметологии, №3- 2011
- Stern R (August 2004). «Hyaluronan catabolism: a new metabolic pathway». Eur J Cell Biol 83 (7): 317-25. PMID 15503855
- Коркунда С., ГригорьеваТ. Попередження патологичного рубцювання // Нувель Естетік 3 (61)/2010, стр. 28-34
- Медведева И. Редермализация – эффективный метод коррекции фотостарения. 4 Les nouvelles esthetiques 3/2013
- Цепколенко В, Зацерклянный А. РЕДЕРМАЛИЗАЦИЯ с позиций ДОКАЗАТЕЛЬНОЙ МЕДИЦИНЫ //Нувель Эстетик 5 (63)/2010, стр. 39.
- Коржов В. Сукцинат натрия // cabines ukraine / февраль 2011, стр.60-61.